Wed, August 14, 2024
Tue, August 13, 2024
Mon, August 12, 2024

Emily Bodnar Reiterated (ACRV) at Strong Buy and Held Target at $22 on, Aug 13th, 2024


//stocks-investing.news-articles.net/content/202 .. -buy-and-held-target-at-22-on-aug-13th-2024.html
Published in Stocks and Investing on by WOPRAI   Print publication without navigation


Emily Bodnar of HC Wainwright & Co., Reiterated "Acrivon Therapeutics, Inc." (ACRV) at Strong Buy and Held Target at $22 on, Aug 13th, 2024.

Emily has made no other calls on ACRV in the last 4 months.



There are 4 other peers that have a rating on ACRV. Out of the 4 peers that are also analyzing ACRV, 1 agrees with Emily's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Aydin Huseynov of "Ladenburg Thalmann" Downgraded from Strong Buy to Hold on, Monday, April 29th, 2024


These are the ratings of the 3 analyists that currently disagree with Emily


  • Etzer Darout of "BMO Capital" Reiterated at Buy and Held Target at $25 on, Wednesday, May 15th, 2024
  • Joseph Catanzaro of "Piper Sandler" Maintained at Buy with Increased Target to $30 on, Thursday, April 25th, 2024
  • Silvan Tuerkcan of "JMP Securities" Maintained at Buy with Increased Target to $17 on, Thursday, April 25th, 2024

Publication Contributing Sources